Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

Marina Chiara Garassino, MD
Published: Tuesday, Oct 31, 2017



Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Garassino says that the future of immunotherapy in NSCLC lies in combinations.

In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.
 
SELECTED
LANGUAGE


Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Garassino says that the future of immunotherapy in NSCLC lies in combinations.

In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x